Login to Your Account

More Pricing Power Won't Be 'NICE' to Biopharma: ABPI

By Nuala Moran
Staff Writer

Tuesday, March 26, 2013

The shape of the UK's new drug pricing regime became clearer when the government confirmed it is handing responsibility for assessing the value of medicines to the National Centre for Health and Clinical Excellence, which has repeatedly clashed with the industry over its decisions on whether drugs should be funded by the National Health Service.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription